JP2025501411A - 重水素化有機化合物およびその使用 - Google Patents
重水素化有機化合物およびその使用 Download PDFInfo
- Publication number
- JP2025501411A JP2025501411A JP2024561731A JP2024561731A JP2025501411A JP 2025501411 A JP2025501411 A JP 2025501411A JP 2024561731 A JP2024561731 A JP 2024561731A JP 2024561731 A JP2024561731 A JP 2024561731A JP 2025501411 A JP2025501411 A JP 2025501411A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- disorder
- formula
- pharma
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263296137P | 2022-01-03 | 2022-01-03 | |
| US63/296,137 | 2022-01-03 | ||
| US202263314466P | 2022-02-27 | 2022-02-27 | |
| US63/314,466 | 2022-02-27 | ||
| US202263345002P | 2022-05-23 | 2022-05-23 | |
| US63/345,002 | 2022-05-23 | ||
| US202263394565P | 2022-08-02 | 2022-08-02 | |
| US63/394,565 | 2022-08-02 | ||
| US202263384988P | 2022-11-25 | 2022-11-25 | |
| US63/384,988 | 2022-11-25 | ||
| PCT/US2023/010055 WO2023130119A1 (en) | 2022-01-03 | 2023-01-03 | Deuterated organic compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501411A true JP2025501411A (ja) | 2025-01-17 |
| JP2025501411A5 JP2025501411A5 (cg-RX-API-DMAC10.html) | 2026-05-13 |
Family
ID=87000385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024561731A Pending JP2025501411A (ja) | 2022-01-03 | 2023-01-03 | 重水素化有機化合物およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12606523B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4460292A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025501411A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240132477A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023204433B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3242755A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL313999A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024008371A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202333671A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023130119A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025010255A2 (en) | 2023-07-02 | 2025-01-09 | Engrail Therapeutics, Inc. | Deuterated organic compounds and uses thereof |
| WO2026011157A1 (en) | 2024-07-05 | 2026-01-08 | Engrail Therapeutics, Inc. | Crystalline forms |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4197243A (en) * | 1975-04-02 | 1980-04-08 | Yamanouchi Pharmaceutical Co., Ltd. | N-1-Benzyl-3-pyrrolidinyl-4-dimethylamino benzamide derivatives |
| US4210660A (en) | 1978-12-20 | 1980-07-01 | Yamanouchi Pharmaceutical Co., Ltd. | Benzamide derivatives |
| TW212139B (cg-RX-API-DMAC10.html) | 1991-04-15 | 1993-09-01 | Yamanouchi Pharma Co Ltd | |
| KR100355130B1 (ko) | 1992-09-18 | 2003-01-30 | 야마노우치세이야쿠 가부시키가이샤 | 하이드로겔서방성정제 |
| US5705498A (en) | 1992-11-05 | 1998-01-06 | Smithkline Beecham Plc. | Piperidine derivatives as 5-HT4 receptor antagonists |
| US6872405B2 (en) | 2001-05-10 | 2005-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Quick-disintegrating tablet in buccal cavity and manufacturing method thereof |
| KR102967223B1 (ko) | 2013-12-03 | 2026-05-19 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| CN104744333A (zh) | 2013-12-26 | 2015-07-01 | 张云 | 一种奈莫必利的生产方法 |
| US20190343827A1 (en) | 2018-05-08 | 2019-11-14 | Izumi Technology, Llc | Deuterated analogs of tariquidar |
| WO2020176597A1 (en) | 2019-02-27 | 2020-09-03 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
| US20210017160A1 (en) | 2019-07-16 | 2021-01-21 | Cyclerion Therapeutics, Inc. | DEUTERATED sGC STIMULATORS |
| JP2025501410A (ja) | 2022-01-03 | 2025-01-17 | エングレイル・セラピューティクス・インコーポレイテッド | 重水素化有機化合物およびその使用 |
| WO2025010255A2 (en) | 2023-07-02 | 2025-01-09 | Engrail Therapeutics, Inc. | Deuterated organic compounds and uses thereof |
-
2023
- 2023-01-03 WO PCT/US2023/010055 patent/WO2023130119A1/en not_active Ceased
- 2023-01-03 AU AU2023204433A patent/AU2023204433B2/en active Active
- 2023-01-03 KR KR1020247025930A patent/KR20240132477A/ko active Pending
- 2023-01-03 TW TW112100105A patent/TW202333671A/zh unknown
- 2023-01-03 JP JP2024561731A patent/JP2025501411A/ja active Pending
- 2023-01-03 IL IL313999A patent/IL313999A/en unknown
- 2023-01-03 CA CA3242755A patent/CA3242755A1/en active Pending
- 2023-01-03 EP EP23735189.5A patent/EP4460292A4/en active Pending
-
2024
- 2024-07-02 MX MX2024008371A patent/MX2024008371A/es unknown
- 2024-07-03 US US18/763,819 patent/US12606523B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20250011280A1 (en) | 2025-01-09 |
| KR20240132477A (ko) | 2024-09-03 |
| AU2023204433A1 (en) | 2024-07-18 |
| WO2023130119A1 (en) | 2023-07-06 |
| MX2024008371A (es) | 2024-12-06 |
| IL313999A (en) | 2024-08-01 |
| AU2023204433B2 (en) | 2026-07-30 |
| EP4460292A4 (en) | 2025-07-16 |
| CA3242755A1 (en) | 2023-07-06 |
| TW202333671A (zh) | 2023-09-01 |
| EP4460292A1 (en) | 2024-11-13 |
| US12606523B2 (en) | 2026-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025501410A (ja) | 重水素化有機化合物およびその使用 | |
| JP5711813B2 (ja) | βセクレターゼ(BACE)の阻害剤として有用な5,6−ジヒドロ−2H−[1,4]オキサジン−3−イル−アミン誘導体 | |
| WO2020182159A1 (zh) | Jak激酶抑制剂及其制备方法和在医药领域的应用 | |
| US20190083420A1 (en) | Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders | |
| CN115884971A (zh) | 取代的哌啶化合物及其用途 | |
| US12606523B2 (en) | Deuterated organic compounds and uses thereof | |
| JP6975515B2 (ja) | Trpa1モデュレーターとしてのスルホニルシクロアルキルカルボキサミド化合物 | |
| US12365650B2 (en) | Deuterated organic compounds and uses thereof | |
| JP2018522831A (ja) | Nr2bnmdaレセプターアンタゴニストとしての3,3−ジフルオロピペリジンカルバメート複素環式化合物 | |
| JP2022036285A (ja) | ピペリジニルノシセプチン受容体化合物 | |
| TWI644914B (zh) | 1,2,4-三唑并[4,3-a]吡啶化合物及其作為MGLUR2受體之正向異位調節劑的用途 | |
| TWI674095B (zh) | 含代謝性麩胺酸性受體第2亞型之正向異構調節劑或正構位激動劑之組合物及其用途 | |
| TW201245197A (en) | Substituted [(5h-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists | |
| CN118804746A (zh) | 氘代有机化合物及其用途 | |
| CN118804910A (zh) | 氘代有机化合物及其用途 | |
| CN113773251A (zh) | 可用作RORγ调节剂的苯胺类化合物 | |
| HK40059280B (en) | ANILINE COMPOUNDS USEFUL AS RORγMODULATORS | |
| HK40083601B (en) | Substituted piperidine compound and application thereof | |
| CN121405680A (zh) | 取代苯并咪唑衍生物及其制备方法和用途 | |
| EA045865B1 (ru) | Замещенные пиперидиновые соединения и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251225 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260416 |